https://novapublishers.com Publisher of Books and Journals in Medicine and Health, Science and Technology and Social Sciences Sat, 14 Jan 2023 18:49:56 +0000 en-US hourly 1 https://wordpress.org/?v=6.1.1 https://novapublishers.com/wp-content/uploads/2018/08/cropped-nova-favicon-32x32.jpg https://novapublishers.com 32 32 https://novapublishers.com/shop/precision-cancer-immunotherapy/ Mon, 10 Oct 2022 20:17:24 +0000 https://novapublishers.com/?post_type=product&p=142671 Andrey S. Bryukhovetskiy, MD, PhD - CEO, Neurovita Clinical Hospital, Moscow, Russia Hari Shanker Sharma - Department of Surgical Sciences, University Hospital, Uppsala University, Uppsala, Sweden Aruna Sharma - Department of Surgical Sciences, University Hospital, Uppsala University, Uppsala, Sweden Series: Cancer Etiology, Diagnosis and Treatments BISAC: MED062000 DOI: 10.52305/TWUU5245 This book reviews the history of immunotherapy and the available therapies including the ones applied in Russia and described in Russian journals, which is frequently unavailable for western readers. The book offers a new standing point towards cancer therapy in general and cancer immunotherapy in particular. It gives special attention to the specific and general mechanisms the cancer cells engage in to evade the surveillance of the immune system and discloses the notion of precision immunotherapy. The term immune insufficiency and its development is discussed in detail. A unique and original inter-disciplinary viewpoint relies on authorial research and three-decade experience in using stem cell therapy for different nosologies.]]> https://novapublishers.com/shop/platinum-based-chemotherapy-clinical-uses-efficacy-and-side-effects/ Sun, 25 Sep 2022 17:04:29 +0000 https://novapublishers.com/?post_type=product&p=125579 Kulmira Nurgali, PhD - Associate Professor, College of Health and Biomedicine, Institute for Health and Sport, Victoria University, Australia; Honorary Associate Professor, Department of Medicine, University of Melbourne, Australia; Head of the Enteric Neuropathy Laboratory, Centre for Health, Research & Education, Sunshine Hospital, Melbourne, Australia; Director, Stem Cells and Regenerative Medicine Program, Australian Institute for Musculoskeletal Science, Australia Raquel Abalo Delgado, PhD - Full Professor, Department of Pharmacology and Nutrition, Universidad Rey Juan Carlos, Madrid, Spain Series: Cancer Etiology, Diagnosis and Treatments BISAC: MED012000; MED062000 DOI: https://doi.org/10.52305/MPSL2859 According to the Global Cancer Observatory, in 2020 the number of new cases of cancer was 19.3 million people in the whole world, with breast, lung, and colorectal cancer comprising 10-11% each of these figures. In the same year, there were almost 10 million deaths from cancer, with lung cancer being the one leading to more deaths (18%). Unfortunately, these figures are only expected to increase, with an estimated incidence of 30.2 million cases in 2040. Thus, cancer is a worldwide public health priority, with a high socio-economic impact. Chemotherapy stands out among the available cancer treatments. Platinum-based chemotherapy is one of the earliest chemotherapeutics introduced to the clinics and it is still the first-line treatment, used alone or in combination with other anti-neoplastic therapy and/or radiation, for many types of cancer in both adults and children. The book Platinum-Based Chemotherapy: Clinical Uses, Efficacy and Side Effects offers the reader a general overview of this therapy, as well as an update on some of the most relevant issues specific to this therapy.]]> https://novapublishers.com/shop/horizons-in-cancer-research-volume-84/ Tue, 26 Jul 2022 20:02:16 +0000 https://novapublishers.com/?post_type=product&p=123568 Hiroto S. Watanabe (Editor) Series: Horizons in Cancer Research BISAC: MED062000 This volume includes eight chapters that describe recent updates in cancer research. Chapter One highlights the benefits of ancillary/consulting care services within pediatric oncology, including social work, psychology, neuropsychology, expressive therapies, child life, chaplaincy, teachers/school liaisons, rehabilitation therapies, nutrition, and palliative care. Chapter Two discusses various generations of chimeric antigen receptors (CAR) and recent efforts in manufacturing CAR T-cells as a therapy for cancer treatment. Chapter Three explores alternative target pathways for putative therapeutic approaches affecting chronic myeloid leukemia cells. Chapter Four reviews research done on the role of epigenetics in the initiation and progression of thyroid cancer. Chapter Five summarizes the literature that implicates the underlying molecular mechanisms of paclitaxel resistance and the potential therapeutic targets to overcome this resistance. Chapter Six deals with the inhibition of autophagy for instigating temozolomide for increasing induction of apoptosis in glioblastoma. Chapter Seven studies the use of vitamin E for leukemic stem cells reprogramming. Finally, Chapter Eight describes new molecular studies for approaches affecting chronic myeloid leukemia cells.]]> https://novapublishers.com/shop/horizons-in-cancer-research-volume-83/ Thu, 09 Jun 2022 13:00:13 +0000 https://novapublishers.com/?post_type=product&p=116798 Hiroto S. Watanabe Series: Horizons in Cancer Research BISAC: MED062000 This volume includes seven chapters that present some of the latest advancements in cancer research. Chapter One studies the correlation between smoking and cancer using the sequenced human genome. Chapter Two discusses glucose-regulated protein 78-mediated regulation of epithelial-mesenchymal transition, the apoptotic and autophagic signaling pathways, and how it can be used as a therapeutic against cancer. Chapter Three discusses new approaches in the treatment of hodgkin lymphoma. Chapter Four includes a review of the etiology, diagnosis and therapeutic management of rare pancreatic tumors. Chapter Five introduces recent progress on the mechanism of action and predictive biomarkers of mitomycin C using a genome-scale CRISPR/Cas9 knockout screening approach. Chapter Six discusses ultrasonography, endometrial sampling, magnetic resonance imaging, and computed tomography in the context of endometrial cancers. Finally, Chapter Seven discusses treatment options for papillary thyroid carcinoma. **Order both the printed version and the e-book together and SAVE!**]]> https://novapublishers.com/shop/meningiomas-from-diagnosis-to-treatment/ Wed, 09 Mar 2022 17:30:32 +0000 https://novapublishers.com/?post_type=product&p=113909 Series: Rare Disorders Research Progress BISAC: MED047000 DOI: https://doi.org/10.52305/BLJA7067 Meningiomas are among the most common primary tumors of the central neoplasm and are probably the most common primary nonglial tumor type. They are also the most common of the extra-axial tumors of the brain. Understanding of meningiomas and their classification, grading and molecular biology and genetics has evolved significantly over the past few decades. Environmental and genetic factors have been implicated in the development of these neoplasms. They arise from meningothelial (arachnoidal cap cells), typically situated in the meninges, near the dura. However, these cells can be found in other locations less commonly which accounts for the development of meningiomas in unusual locations (sometimes outside the central nervous system). Although the majority of these tumors are considered low grade neoplasms, classification and grading schemas have identified subtypes of meningiomas that are associated with more aggressive behavior or have unusual presentations. The fourteen chapters in this book address some of these various aspects of this diverse group of tumors. **Order both the printed version and the e-book together and SAVE!**]]> https://novapublishers.com/shop/how-plant-flavonoids-affect-the-outcome-of-hormonal-and-biological-cancer-therapies-a-handbook-for-doctors-and-patients/ Thu, 03 Feb 2022 13:49:17 +0000 https://novapublishers.com/?post_type=product&p=111636 Series: Cancer Etiology, Diagnosis and Treatments BISAC: HEA039030 DOI: https://doi.org/10.52305/HATJ3532 Cancer is a steadily increasing public health concern and severe socio-economic burden all over the world. Based on the current statistics of the WHO, almost 10 million people lost their lives due to malignant disorders in 2020, implying that one in every six deaths is due to cancer. In parallel, the global population of cancer survivors is also growing, propelled by advances in early detection, diagnosis and treatment methods, but also by demographic aging. More and more cancer patients today decide to use dietary supplements and herbal products in order to enhance their overall health, delay the progression of disease, augment the outcome of conventional therapies, mitigate diagnosis-related depression and anxiety, and alleviate drug-associated side effects, doing it mostly unbeknownst to their health care providers. Such over-the-counter supplements usually contain diverse flavonoids, such as catechins from green tea extracts, isoflavones from soy products, flavanones from citrus oils or silibinin from milk thistle seeds, just to name a few. A variety of flavonoid-rich products are often consumed concurrently with standard cancer therapies, without anticipating and understanding the potential interactions between plant-derived bioactive flavonoids and clinically used anticancer drugs. In this book, diverse effects of these polyphenolic phytochemicals on hormonal and targeted biological cancer therapies are covered, being a reasoned follow-up to the two previous books Plant Flavonoids Affect Cancer Chemotherapeutic Efficacy: A Handbook for Doctors and Patients (2019) and Dietary Flavonoids Interfere with Cancer Radiotherapy (2019). Besides naturally occurring flavonoids, the impact of flavonoid-rich plant extracts as well as semisynthetic derivatives on anticancer activities of co-administered hormonal and targeted drugs are thoroughly discussed, and some indicative recommendations to patients undergoing hormonal cancer therapies or targeted biological cancer therapies are provided. **Order both the printed version and the e-book together and SAVE!**]]> https://novapublishers.com/shop/horizons-in-cancer-research-volume-82/ Sat, 16 Oct 2021 20:01:43 +0000 https://novapublishers.com/?post_type=product&p=107300 Hiroto S. Watanabe (Editor) Series: Horizons in Cancer Research BISAC: MED062000 DOI: https://doi.org/10.52305/KWEJ9169 This volume presents some of the latest research surrounding cancer. Chapter One provides a background on the importance of magnesium homeostasis, reviews the pre-clinical and clinical studies using magnesium therapy for cisplatin-induced acute kidney injury, and proposes future investigations to improve the translatability of these results to cancer treatment. Chapter Two discusses various liquid biomarkers of ovarian cancer such as exosomes, cell free DNA, miRNAs, circulating tumor cells, secretory proteins and autoantibodies and their subsequent detection via various nanobiosensors. Chapter Three explores the potential of mouse xenograft models for elucidating resistance mechanisms to cancer therapeutics. Chapter Four summarizes melatonin’s beneficial effects in ovarian follicular cells and oocytes, followed by a comprehensive description of melatonin as an alternative treatment for ovarian cancer. Chapter Five deals with the gene signatures potentially implicated in the development of endometrial cancer. Lastly, Chapter Six updates current understanding of the role of glucocorticoid receptor-mediated actions in triple-negative breast cancer.]]> https://novapublishers.com/shop/burkitt-lymphoma-diagnosis-risk-factors-and-treatment/ Mon, 20 Sep 2021 17:00:18 +0000 https://novapublishers.com/?post_type=product&p=102627 Douglas V. Berthelot (Editor) Series: Cancer Etiology, Diagnosis and Treatments BISAC: MED062020 DOI: https://doi.org/10.52305/VODC3429 Burkitt lymphoma (BL) is a form of non-Hodgkin’s lymphoma in which cancer starts in immune cells called B-cells. If left untreated, it is rapidly fatal. Chapter One of this monograph evaluates the etiology, pathological issues, diagnosis, clinical manifestations, epidemiology, research, innovation and treatment issues of BL using the clinical systematic review research method and experts’ opinion analysis approach. Chapter Two reviews the spectrum, unique characteristics and special management considerations when BL develops in specific subgroups of patients with primary immune deficiency disorders. Chapter Three reviews the incidence, clinicopathological and epidemiologic features, treatment and outcome data available in pediatric and adult patients with post solid organ transplant BL. Chapter Four focuses on the pathobiology and the treatment of first-line and relapsed/refractory cases of BL and describes new therapeutic strategies which could improve results in this pathology. Chapter Five examines the therapeutic advances in BL and its variants. Finally, Chapter Six explores and emphasizes the trends and issues in research and innovation in the characteristics, clinical updates and management approaches of BL.]]> https://novapublishers.com/shop/bridging-the-gap-in-this-era-of-cancer-immunotherapy/ Mon, 20 Sep 2021 16:40:58 +0000 https://novapublishers.com/?post_type=product&p=101227 Series: Cancer Etiology, Diagnosis and Treatments BISAC: MED062000 “These chapters provide an extensive review of travenous vitamin C for the treatment of cancer. The long history of vitamin C as a nutritional supplement to combat scurvy to a potential radio-chemotherapeutic agent is discussed.” - Joseph J. Cullen, Professor of Surgery, University of Iowa, USA  Recognizing rare diseases’ impracticability of having extensive clinical trials necessary for regulatory approval, the US Orphan Drug Act appropriately facilitates the commercialization of “orphan drugs”. However, even common cancers also have rather specific but uncommon clinical situations for which extensive clinical trials are hardly practicable. Moreover, although such very costly and extensive trials often depend on industry support, uncommon situations are unattractive. Eventually, many specific treatments for designated clinical oncology situations often lack regulatory approvals merely because of suboptimal trial data. Now, this EBM (evidence-based medicine) book by expert authors with first-hand clinical experience is about off-label but acceptable treatment options. The attempt is to patch up the low response rates and considerable adverse events of novel immunotherapy. Currently, without any such off-label treatments, some cancer patients may well be left out in the cold. Although off-label treatments lack regulatory approval, they are backed by EBM and have good safety profiles. It’s inappropriate to announce “nothing else can be done” merely because all approved options have already been exhausted. In expert hands, despite the “on compassionate grounds” proviso, the safety profiles of such off-label prescriptions may even compare favorably with orthodox chemotherapy given at top doses.]]> https://novapublishers.com/shop/mesothelioma-risk-factors-treatment-and-prognosis/ Sun, 05 Sep 2021 17:07:49 +0000 https://novapublishers.com/?post_type=product&p=103616 Albert K. Martin (Editor) Series: Cancer Etiology, Diagnosis and Treatments BISAC: MED062000 DOI: https://doi.org/10.52305/FRKL1404 Mesothelioma is a type of cancer in which tumors form in the tissue that lines the lungs, heart, stomach, and other organs. While mesothelioma is relatively rare, it represents a serious health crisis as the disease is aggressive and often fatal. This book includes five chapters that detail the treatment and prognosis of the disease as well as the factors that put a person at risk for developing mesothelioma. Chapter One describes the most promising emerging immunotherapy combinations for the treatment of malignant pleural mesothelioma, discussing the biological rational underlying their development as well as the issues surrounding their clinical development. Chapter Two provides an overview of malignant mesothelioma, describing the history of its diagnosis and treatment as well as the role that asbestos exposure and other factors play in its development. Chapter Three revises the role of the main inflammatory and immunological markers as prognostic indicators in malignant pleural mesothelioma and discusses the surgical effects on immune response against cancer. Chapter Four explores the main cancer markers utilized for mesothelioma diagnosis as well as the new developments in the field. Lastly, Chapter Five examines the various surgical options available for removing pleural tumors.]]> https://novapublishers.com/shop/combination-therapies-and-their-effectiveness-in-breast-cancer-treatment/ Mon, 16 Aug 2021 14:35:03 +0000 https://novapublishers.com/?post_type=product&p=104950 Series: Cancer Etiology, Diagnosis and Treatments BISAC: HEA039030 DOI: https://doi.org/10.52305/WXJL6770 This book highlights up-to-date and novel information with clinical aspects regarding breast cancer disease. It covers aspects of breast cancer ranging from epidemiology, biology and molecular classification, to currently available and potentially new therapeutic options for breast cancer. It highlights insights into breast cancer at the molecular level with a holistic approach to use combinational strategies involving various therapies for targeting different pathways involved in this particular malignancy. This book contains a range of latest resources, including schematic illustrations, recent reviews, and information for patients with breast cancer. Various novel biomarkers that are under clinical investigation will also be discussed in this book. Furthermore, the relapse and recurrence after treatment with various therapies presents a great problem, as it develops resistance to which combinational strategy may prove to be a promising approach, and in this book, we have discussed all the aspects of combination therapy in breast cancer. People including students, research scholars, educators, pharmaceutical professionals, clinicians, researchers, practitioners and patients as well as their family members will find this book very much useful.]]> https://novapublishers.com/shop/oral-squamous-cell-carcinoma-from-diagnosis-to-treatment/ Thu, 08 Jul 2021 13:18:11 +0000 https://novapublishers.com/?post_type=product&p=99519 Matthew Rabin (Editor) Series: Cancer Etiology, Diagnosis and Treatments BISAC: MED062000 This monograph consists of five chapters that describe the diagnosis and treatment of oral squamous cell carcinoma (OSCC), which is the most common malignant epithelial neoplasm affecting the oral cavity. Chapter One deals with different potentially malignant disorders in the development of OSCC, diagnostic methods of OSCC, the pertinence of biomarkers in OSCC therapy, classification of biomarkers, existing biomarkers in different stages of OSCC and the challenges of developing new biomarkers. Chapter Two is focused on principles, systems, technologies, therapeutic approaches, safety and toxicity and patents comprising drug delivery systems for local oral squamous cell carcinoma treatment. Chapter Three aims to highlight a detailed critical review of previous literature on putative cancer stem cell pathways for oral carcinoma and draw interest in targeting the most common cancer stem cell markers as a therapeutic regimen for oral cancer preneoplastic tumors, metastasis, and treatment progression. Chapter Four aims to cover the recent developments in nanotechnology-based drug delivery systems, advanced nanomedicines and their diagnostics as well as therapeutic applications in OSCC. Finally, Chapter 5 aims to elaborate on the importance of biomarkers as an early diagnostic tool in detecting oral squamous cell carcinoma.]]>